Sunil Bhonsle Net Worth

The estimated Net Worth of Sunil Bhonsle is at least $763 Thousand dollars as of 18 July 2016. Sunil Bhonsle owns over 10,000 units of Titan Pharmaceuticals, (de) stock worth over $763,304 and over the last 9 years Sunil sold TTNP stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Sunil Bhonsle TTNP stock SEC Form 4 insiders trading

Sunil has made over 3 trades of the Titan Pharmaceuticals, (de) stock since 2016, according to the Form 4 filled with the SEC. Most recently Sunil bought 10,000 units of TTNP stock worth $49,600 on 18 July 2016.

The largest trade Sunil's ever made was buying 11,763 units of Titan Pharmaceuticals, (de) stock on 22 February 2016 worth over $41,876. On average, Sunil trades about 3,943 units every 26 days since 2016. As of 18 July 2016 Sunil still owns at least 135,578 units of Titan Pharmaceuticals, (de) stock.

You can see the complete history of Sunil Bhonsle stock trades at the bottom of the page.

What's Sunil Bhonsle's mailing address?

Sunil's mailing address filed with the SEC is 400 OYSTER POINT BLVD., SUITE 505, , S SAN FRANCISCO, CA, 94080.

Insiders trading at Titan Pharmaceuticals, (de)

Over the last 9 years, insiders at Titan Pharmaceuticals, (de) have traded over $4,610,001 worth of Titan Pharmaceuticals, (de) stock and bought 3,252,657 units worth $2,558,794 . The most active insiders traders include David E.Activist Investing ..., James R Mcnab, and Marc Rubin. On average, Titan Pharmaceuticals, (de) executives and independent directors trade stock every 204 days with the average trade being worth of $2,815,253. The most recent stock trade was executed by David E.Activist Investing ... on 21 June 2023, trading 3,747,968 units of TTNP stock currently worth $4,610,001.

What does Titan Pharmaceuticals, (de) do?

titan pharmaceuticals inc. is developing proprietary therapeutics primarily for the treatment of serious medical disorders. the company's lead product is probuphine®, the first and only commercialized treatment of opioid dependence to provide continuous, around-the-clock blood levels of buprenorphine for six months following a single procedure. it was approved by the u.s. food and drug administration in may 2016 and is being commercialized in the u.s. by partner braeburn pharmaceuticals. probuphine employs titan's proprietary drug delivery system proneura™, which is capable of delivering sustained, consistent levels of medication for up to 12 months. the proneura technology has the potential to be used in developing products for treating other chronic conditions such as parkinson's disease and hypothyroidism, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes.

Complete history of Sunil Bhonsle stock trades at Titan Pharmaceuticals, (de)

Titan Pharmaceuticals, (de) executives and stock owners

Titan Pharmaceuticals, (de) executives and other stock owners filed with the SEC include:

• Marc Rubin,
  Executive Chairman of the Board, Chief Executive Officer
• Katherine DeVarney,
  President, Chief Operating Officer, Chief Scientific Officer, Director
• Dr. Katherine L. Beebe-DeVarney Ph.D.,
  Pres, COO & Director
• Dr. Marc Rubin M.D.,
  Exec. Chairman & Principal Exec. Officer
• Stephen Kilmer,
  Investor Relations
• James McNab,
  Independent Director
• M. David MacFarlane,
  Independent Director
• Joseph Akers,
  Independent Director
• Scott Smith,
  Independent Director
• Joe Schrei,
  Exec. Director of Commercial Operations
• Jennifer Kiernan,
  Exec. Assistant to CEO & Investor Communications Coordinator
• Mike Fritz,
  National Sales Director
• Brian E. Crowley,
  VP of Fin.
• Dane Hallberg,
  See Remarks
• Eurelio M Cavalier,
  Director
• Sunil Bhonsle,
  President and CEO
• Choon Hau Choong,
  10% owner
• Rajinder Kumar,
  Director
• Matthew Charles Mc Murdo,
  Director
• David Natan,
  Director
• Peter Louis Chasey,
  Director
• Federico Seghi Recli,
  Director
• Avraham Ben Tzvi,
  Director
• David E. Lazar,
  Chief Executive Officer
• Eric Howard Greenberg,
  Director
• Katherine Beebe,
  President and COO
• David E.Activist Investing ...,
  Chief Executive Officer